DNA HIVIS + MVA-CMDR

DNA HIVIS + MVA-CMDR is a combination investigational vaccine regimen for the prevention of human immunodeficiency virus type 1 (HIV-1) infection. The regimen uses a prime-boost strategy where priming is performed with multigene, multiclade plasmid DNA vaccines (HIVIS-DNA), followed by boosting with a recombinant modified vaccinia Ankara vector expressing analogous or heterologous HIV-1 genes (MVA-CMDR). The DNA component encodes antigens from multiple subtypes of HIV-1 (A, B, C), while the MVA vector expresses Gag and Pol from subtype A and Env from CRF01_AE. This approach aims to induce broad humoral and cellular immune responses against diverse strains of HIV-1 by targeting key viral proteins such as Env, Gag, and Pol. Clinical studies have shown that this regimen elicits strong antibody responses—especially to V2/V3/gp41 regions—and robust T-cell responses in both adults and children. The vaccine has been evaluated in several phase I/II trials for safety and immunogenicity[1][2][4][5].

Other names

HIVIS DNA/MVA-CMDRHIV-DNA/MVA-CMDR